Use: Labeled indications
- INDICATIONS AND USAGE: Isosorbide Mononitrate Tablets are indicated for the prevention and treatment of angina pectoris due to coronary artery disease.
Full indications and usage US FDA label
INDICATIONS AND USAGE: Isosorbide Mononitrate Tablets are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
Contraindications
CONTRAINDICATIONS: Isosorbide mononitrate is contraindicated in patients who are allergic to it. Do not use isosorbide mononitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia. Do not use isosorbide mononitrate in patients who are taking the soluble guanylate cyclase stimulator riociguat. Concomitant use can cause hypotension.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION: The recommended regimen of Isosorbide Mononitrate Tablets is 20 mg twice daily, with the doses seven hours apart. A starting dose of 5 mg (½ tablet of the 10 mg dosing strength) might be appropriate for persons of particularly small stature but should be increased to at least 10 mg by the second or third day of therapy.
Dosage adjustments are not necessary for elderly patients or patients with altered hepatic or renal function. As noted above (Clinical Pharmacology), multiple studies of organic nitrates have shown that maintenance of continuous 24-hour plasma levels results in refractory tolerance. The asymmetric (2 doses, 7 hours apart) dosing regimen for Isosorbide Mononitrate Tablets provides a daily nitrate-free interval to minimize the development of tolerance.
As also noted under Clinical Pharmacology, well-controlled studies have shown that tolerance to Isosorbide Mononitrate Tablets occurs to some extent when using the twice-daily regimen in which the two doses are given seven hours apart. This regimen has been shown to have antianginal efficacy beginning one hour after the first dose and lasting at least seven hours after the second dose.
The duration (if any) of antianginal activity beyond fourteen hours has not been studied. In clinical trials, isosorbide mononitrate has been administered in a variety of regimens and doses. Doses above 20 mg twice a day (with the doses seven hours apart) have not been adequately studied. Doses of 5 mg twice a day are clearly effective (effectiveness based on exercise tolerance) for only the first day of a twice-a-day (with doses 7 hours apart) regimen.
Dosing: Altered kidney function
Dosage adjustments are not necessary for elderly patients or patients with altered hepatic or renal function.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Sustained-release capsule: 30 mg, 60 mg
- Tablet: 10 mg, 20 mg
- Controlled-release fim-coated tablet: 60 mg
- Prolonged-release tablet: 60 mg
Registered products in the Philippines
8 products registered with the Food and Drug Administration (FDA) Philippines list Isosorbide-5-mononitrate as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Isosorbide Mononitrte (1 product). Products registered under these spellings are included in the table and marked.
All registered products8
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcunasynIsosorbide-5-Mononitrate | 20mg TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-9030 | Aug 17, 2030 | |
AngistadIsosorbide-5-Mononitrate | 60mg Sustained Release CapsulePVC/PVDC Aluminum Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Valpharma International S.p.A.Italy | STADA Philippines Inc.Trader: STADA Arzneimittel AG | DRP-624 | Oct 9, 2027 | |
Imdur DurulesIsosorbide-5-Mononitrate | 60 mg Prolonged-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Laboratorios Alcala Farma, S.L.Spain | Zuellig Pharma Corporation | DR-XY23150 | Oct 18, 2027 | |
60 mg Controlled-Release Fim-Coated TabletAlu/Orange Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Shou Chan Industrial Co. Ltd.Taiwan | New Smart Formulae Trading Corp. | DR-XY37590 | Mar 10, 2027 | ||
Monobide-10Isosorbide-5-Mononitrate | 10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-6832 | Sep 15, 2031 | |
Monobide-20Isosorbide-5-Mononitrate | 20 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-6833 | Sep 15, 2031 | |
MontraIsosorbide-5-Mononitrate | 30 mg Sustained-Release CapsulePVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Unilab, Inc. | DR-XY36606 | Sep 10, 2029 | |
MontraIsosorbide-5-Mononitrate | 60 mg Sustained-Release CapsulePVC Blister Pack x 10s Box of 100s | RxVAT-exempt | Inventia Healthcare Pvt. Ltd.India | UNILAB, INC. | DR-XY36604 | Sep 10, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS: Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.
The benefits of isosorbide mononitrate in patients with acute myocardial infarction or congestive heart failure have not been established. Because the effects of isosorbide mononitrate are difficult to terminate rapidly, this drug is not recommended in these settings. If isosorbide mononitrate is used in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Omnivium Pharmaceuticals LLC at 1-888-807-1048 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Headache is the most frequent side effect and was the cause of 2% of all dropouts from controlled-clinical trials. Headache decreased in incidence after the first few days of therapy.
The following table shows the frequency of adverse reactions observed in 1% or more of subjects in 6 placebo-controlled trials, conducted in the United States and abroad. The same table shows the frequency of withdrawal for these adverse reactions. In many cases the adverse reactions were of uncertain relation to drug treatment.
Frequency of Adverse Reactions (Discontinuations)* 6 Placebo-Controlled Studies Dose Placebo 5 mg 10 mg 20 mg Patients 160 54 52 159 Headache 6% (0%) 17% (0%) 13% (0%) 35% (5%) Fatigue 2% (0%) 0% (0%) 4% (0%) 1% (0%) Upper Respiratory Infection <1% (0%) 0% (0%) 4% (0%) 1% (0%) Pain <1% (0%) 4% (0%) 0% (0%) <1% (0%) Dizziness 1% (0%) 0% (0%) 0% (0%) 4% (0%) Nausea <1% (0%) 0% (0%) 0% (0%) 3% (2%) Increased Cough <1% (0%) 0% (0%) 2% (0%) <1% (0%) Rash 0% (0%) 2% (2%) 0% (0%) <1% (0%) Abdominal Pain <1% (0%) 0% (0%) 2% (0%) 0% (0%) Allergic Reaction 0% (0%) 0% (0%) 2% (0%) 0% (0%) Cardiovascular Disorder 0% (0%) 2% (0%) 0% (0%) 0% (0%) Chest Pain <1% (0%) 0% (0%) 2% (0%) <1% (0%) Diarrhea 0% (0%) 0% (0%) 2% (0%) 0% (0%) Flushing 0% (0%) 0% (0%) 2% (0%) 0% (0%) Emotional Lability 0% (0%) 2% (0%) 0% (0%) 0% (0%) Pruritus 1% (0%) 2% (2%) 0% (0%) 0% (0%) *Some individuals discontinued for multiple reasons. Other adverse reactions, each reported by fewer than 1% of exposed patients, and in many cases of uncertain relation to drug treatment, were: Cardiovascular: acute myocardial infarction, apoplexy, arrhythmias, bradycardia, edema, hypertension, hypotension, pallor, palpitations, tachycardia.
Dermatologic: sweating. Gastrointestinal: anorexia, dry mouth, dyspepsia, thirst, vomiting, decreased weight. Genitourinary: prostatic disorder. Miscellaneous: amblyopia, back pain, bitter taste, muscle cramps, neck pain, paresthesia, susurrus aurium. Neurologic: anxiety, impaired concentration, depression, insomnia, nervousness, nightmares, restlessness, tremor, vertigo.
Respiratory: asthma, dyspnea, sinusitis. Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients; for further discussion of its diagnosis and treatment see under Overdosage.
Adverse reaction frequency tables (US label) US FDA label
| 6 Placebo-Controlled Studies | ||||
| Dose | Placebo | 5 mg | 10 mg | 20 mg |
| Patients | 160 | 54 | 52 | 159 |
| Headache | 6% (0%) | 17% (0%) | 13% (0%) | 35% (5%) |
| Fatigue | 2% (0%) | 0% (0%) | 4% (0%) | 1% (0%) |
| Upper Respiratory Infection | <1% (0%) | 0% (0%) | 4% (0%) | 1% (0%) |
| Pain | <1% (0%) | 4% (0%) | 0% (0%) | <1% (0%) |
| Dizziness | 1% (0%) | 0% (0%) | 0% (0%) | 4% (0%) |
| Nausea | <1% (0%) | 0% (0%) | 0% (0%) | 3% (2%) |
| Increased Cough | <1% (0%) | 0% (0%) | 2% (0%) | <1% (0%) |
| Rash | 0% (0%) | 2% (2%) | 0% (0%) | <1% (0%) |
| Abdominal Pain | <1% (0%) | 0% (0%) | 2% (0%) | 0% (0%) |
| Allergic Reaction | 0% (0%) | 0% (0%) | 2% (0%) | 0% (0%) |
| Cardiovascular Disorder | 0% (0%) | 2% (0%) | 0% (0%) | 0% (0%) |
| Chest Pain | <1% (0%) | 0% (0%) | 2% (0%) | <1% (0%) |
| Diarrhea | 0% (0%) | 0% (0%) | 2% (0%) | 0% (0%) |
| Flushing | 0% (0%) | 0% (0%) | 2% (0%) | 0% (0%) |
| Emotional Lability | 0% (0%) | 2% (0%) | 0% (0%) | 0% (0%) |
| Pruritus | 1% (0%) | 2% (2%) | 0% (0%) | 0% (0%) |
Pharmacokinetics
Taking account of the relatively long half-life of isosorbide mononitrate this result is consistent with those obtained for other organic nitrates.
When radiolabelled isosorbide mononitrate was administered to humans in order to elucidate the metabolic fate, about half of the dose was found denitrated and renally excreted as isosorbide and sorbitol.
Only 2% of the dose was excreted as unchanged drug.
The overall elimination half-life of isosorbide mononitrate is about 5 hours.
When radiolabelled isosorbide mononitrate was administered to humans, 93% of the dose was excreted within 48 hours into the urine.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY: Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (ISDN), and most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter.
Dilation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload).
Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction and coronary dilatation remains undefined. Pharmacodynamics: Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration.
This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the antianginal efficacy of continuously-delivered nitrates. In the large majority of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy.
Attempts to overcome tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their antianginal efficacy been restored. The drug-free interval sufficient to avoid tolerance to isosorbide mononitrate has not been completely defined.
In the only regimen of twice-daily isosorbide mononitrate that has been shown to avoid development of tolerance, the two doses of Isosorbide Mononitrate Tablets are given 7 hours apart, so there is a gap of 17 hours between the second dose of each day and the first dose of the next day. Taking account of the relatively long half-life of isosorbide mononitrate this result is consistent with those obtained for other organic nitrates.
The asymmetric twice-daily regimen of Isosorbide Mononitrate Tablets successfully avoided significant rebound/withdrawal effects. The incidence and magnitude of such phenomena have appeared, in studies of other nitrates, to be highly dependent upon the schedule of nitrate administration. Pharmacokinetics: Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract.
In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The absolute bioavailability of isosorbide mononitrate from Isosorbide Mononitrate Tablets is nearly 100%. Peak plasma concentrations usually occur in about 30-60 minutes. Isosorbide mononitrate exhibits dose proportionality over the recommended dose range.
Food does not significantly affect the absorption or bioavailability of Isosorbide Mononitrate Tablets. Metoprolol coadministration did not change the pharmacokinetics of isosorbide mononitrate. The volume of distribution is approximately 0.6 L/kg. Plasma protein binding of isosorbide mononitrate was found to be less than 5%.
When radiolabelled isosorbide mononitrate was administered to humans in order to elucidate the metabolic fate, about half of the dose was found denitrated and renally excreted as isosorbide and sorbitol. One quarter of the dose was accounted for as conjugates of the parent drug in the urine. None of these metabolites is vasoactive.
Only 2% of the dose was excreted as unchanged drug. The overall elimination half-life of isosorbide mononitrate is about 5 hours. The rate of clearance is the same in healthy young adults, in patients with various degrees of renal, hepatic or cardiac dysfunction and in the elderly. When radiolabelled isosorbide mononitrate was administered to humans, 93% of the dose was excreted within 48 hours into the urine.
Renal excretion was virtually complete after 5 days; fecal excretion amounted to only 1% of the dose. Isosorbide mononitrate has no known effect on renal and hepatic function. In patients with varying degrees of renal failure, dosage adjustment does not appear necessary. In patients with liver cirrhosis, the pharmacokinetic parameters after a single dose of isosorbide mononitrate were similar to the values found in healthy volunteers.
Isosorbide mononitrate is significantly removed from the blood during hemodialysis; however, an additional dose to compensate for drug lost is not necessary. In patients undergoing continuous ambulatory peritoneal dialysis, blood levels are similar to patients not on dialysis. Clinical Trials: The acute and chronic antianginal efficacy of isosorbide mononitrate has been confirmed in clinical trials.
The clinical efficacy of isosorbide mononitrate was studied in 21 stable angina pectoris patients. After single dose administration of Isosorbide Mononitrate Tablets, 20 mg, the exercise capacity was increased by 42.7% after one hour, 29.6% after 6 hours, and by 25% after eight hours when compared to placebo. Controlled trials of single doses of Isosorbide Mononitrate Tablets have demonstrated that antianginal activity is present about 1 hour after dosing, with peak effect seen from 1-4 hours after dosing.
In one multicenter placebo-controlled trial, isosorbide mononitrate was found to be safe and effective during acute and chronic (3 weeks) treatment of angina pectoris. Two hundred fourteen (214) patients were enrolled in the trial; 54 patients were randomized to receive placebo and 106 patients were randomized to receive 10 or 20 mg of Isosorbide Mononitrate Tablets twice daily seven hours apart.
The largest effect of isosorbide mononitrate, compared to placebo, was on day one - dose one. Although 14 hours after the first dose of day 14, the increase in exercise tolerance due to isosorbide mononitrate was statistically significant, the increase was about half of that seen 2 hours after the first dose of day one.
On day 21, two hours after the first dose the effect of isosorbide mononitrate was 60 to 70% of that seen on day one.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Isosorbide-5-Mononitrate 30 mg MR Tablet | ₱5.00–₱11.00Reference ₱7.65 | per tablet | DPRI procurement range |
| Isosorbide-5-Mononitrate 60 mg MR Tablet | ₱5.00–₱12.00Reference ₱7.00 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Isosorbide-5-Mononitrate |
| PNF listing | Oral: 40 mg tablet |
| PNF listing | Oral: 30 mg and 60 mg MR tablet/capsule |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. isosorbide mononitrate · OMNIVIUM PHARMACEUTICALS LLC. [US FDA-approved label, version 2, August 6, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdf01e14-778b-4b3f-8372-1c18f266fb98
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .